AR021876A1 - COMBINATION THERAPY FOR HCV INDUCTION OF RIBAVIRINA - INTERFERON ALFA PEGILADO - Google Patents
COMBINATION THERAPY FOR HCV INDUCTION OF RIBAVIRINA - INTERFERON ALFA PEGILADOInfo
- Publication number
- AR021876A1 AR021876A1 ARP990106462A ARP990106462A AR021876A1 AR 021876 A1 AR021876 A1 AR 021876A1 AR P990106462 A ARP990106462 A AR P990106462A AR P990106462 A ARP990106462 A AR P990106462A AR 021876 A1 AR021876 A1 AR 021876A1
- Authority
- AR
- Argentina
- Prior art keywords
- interferon alfa
- effective amount
- weeks
- hcv
- therapeutically effective
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se revela el uso de ribavirina e interferon alfa pegilado para la manufactura de composiciones farmacéuticas para tratar un paciente con infeccion cronicade hepatitis C, por ejemplo un paciente que tiene un genotipo 1,2 o 3 de VHC, para erradicar elARN del VHC detectable, mediante un método que comprende laadministracion de una cantidad efectiva de ribavirina en asociacion con una cantidad efectiva de interferon alfa pegilado, que se caracteriza en que eltratamiento de los pacientes que tieneninfecciones cronicas de hepatitis C se efectua en dos períodos de tratamiento;(a)un primer período de tratamiento de almenos 20 a 30 semanas, en el cual se administran una cantidad terapéuticamente efectiva de ribavirina y una cantidad dosificantede induccion terapéuticamenteefectiva de interferon alfa pegilado, por ejemplo, interferon alfa-2b pegilado suficiente para al menos disminuir sustanciamente, y preferentemente paraerradicar el ARN de VHC detectable; y b) un segundo período detratamie nto de al menos de 20 a 30 semanas, donde una cantidad terapéuticamente efectiva deribavirina y una cantidad terapéuticamente efectiva de interferon alfa pegilado se administran en forma suficiente para mantener el ARN del VHC nodetectable,durante a l menos de 20 a 30 semanas luego de finalizar el primer período de tratamiento y para mantener el ARN del VHC no detectable durante al menos 24semanas, luego de finalizar el segundo período de tratamiento.The use of pegylated ribavirin and interferon alfa is disclosed for the manufacture of pharmaceutical compositions for treating a patient with chronic hepatitis C infection, for example a patient who has a 1.2 or 3 HCV genotype, to eradicate detectable HCV RNA, by a method comprising administering an effective amount of ribavirin in association with an effective amount of pegylated interferon alfa, which is characterized in that the treatment of patients who have chronic hepatitis C infections is carried out in two treatment periods; (a) a first treatment period of at least 20 to 30 weeks, in which a therapeutically effective amount of ribavirin and a dosing amount of therapeutically effective induction of pegylated interferon alpha are administered, for example, pegylated interferon alfa-2b sufficient to at least substantially decrease, and preferably to eradicate HCV RNA detectable; and b) a second treatment period of at least 20 to 30 weeks, where a therapeutically effective amount of deribavirin and a therapeutically effective amount of pegylated interferon alfa are administered sufficiently to keep the HCV RNA nodetectable, for at least 20 to 30 weeks after the end of the first treatment period and to keep HCV RNA undetectable for at least 24 weeks, after the end of the second treatment period.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21587698A | 1998-12-18 | 1998-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR021876A1 true AR021876A1 (en) | 2002-08-07 |
Family
ID=22804768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990106462A AR021876A1 (en) | 1998-12-18 | 1999-12-16 | COMBINATION THERAPY FOR HCV INDUCTION OF RIBAVIRINA - INTERFERON ALFA PEGILADO |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1140143A2 (en) |
| JP (1) | JP2003507322A (en) |
| AR (1) | AR021876A1 (en) |
| AU (1) | AU2157000A (en) |
| CA (1) | CA2354536A1 (en) |
| PE (1) | PE20001369A1 (en) |
| WO (1) | WO2000037110A2 (en) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| AP2006003708A0 (en) | 2000-05-26 | 2006-08-31 | Idenix Cayman Ltd | Methods and compositions for treating flavivirusesand pestiviruses |
| EP2132984A3 (en) * | 2000-06-30 | 2010-11-03 | ZymoGenetics, L.L.C. | Interferon-like protein ZCYTO21 |
| US7208167B2 (en) | 2000-08-07 | 2007-04-24 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis C with thymosin and peptide combination therapy |
| EP1311279B1 (en) * | 2000-08-07 | 2006-12-20 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis c with thymosin, interferon and ribavirin |
| HUP0301444A3 (en) * | 2000-10-18 | 2007-05-29 | Schering Corp | The use of ribavirin-pegylated interferon alfa for the preparation of pharmaceutical compositions for the treatment of hcv infection |
| US7910313B2 (en) | 2001-04-20 | 2011-03-22 | Zymogenetics, Inc. | Cytokine protein family |
| EP1501936B1 (en) | 2001-04-20 | 2008-08-06 | ZymoGenetics, Inc. | Cytokine protein family |
| US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| EP2799442A1 (en) | 2002-06-28 | 2014-11-05 | IDENIX Pharmaceuticals, Inc. | Modified 2' and 3' -nucleoside prodrugs for treating flaviridae infections |
| PL374781A1 (en) | 2002-06-28 | 2005-10-31 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| PL377342A1 (en) | 2002-11-15 | 2006-01-23 | Idenix (Cayman) Limited | 2'-branched nucleosides and flaviviridae mutation |
| TR201906767T4 (en) | 2003-05-30 | 2019-05-21 | Gilead Pharmasset Llc | Modified fluorinated nucleoside analogs. |
| RU2371195C2 (en) * | 2003-08-13 | 2009-10-27 | Говард Дж. Смит Энд Эссошиэйтс Пти Лтд | Method of virus infection treatment |
| CN101023094B (en) | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives |
| SG158136A1 (en) | 2004-09-14 | 2010-01-29 | Pharmasset Inc | Preparation of 2`-fluoro-2`- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| PL2061513T3 (en) * | 2007-09-14 | 2011-12-30 | Merck Sharp & Dohme | Method of treating hepatitis c patients |
| TW200946541A (en) | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
| EP2376515A1 (en) | 2008-12-23 | 2011-10-19 | Pharmasset, Inc. | Synthesis of purine nucleosides |
| ES2623016T3 (en) | 2008-12-23 | 2017-07-10 | Gilead Pharmasset Llc | 6-O-substituted 2-amino purine nucleoside phosphoramidates |
| KR20110098849A (en) | 2008-12-23 | 2011-09-01 | 파마셋 인코포레이티드 | Nucleoside analogs |
| WO2010117936A1 (en) * | 2009-04-06 | 2010-10-14 | Schering Corporation | Combinations of a hcv inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent |
| TWI576352B (en) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | Nucleoside phosphoramidates |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| UA122959C2 (en) | 2010-03-31 | 2021-01-27 | Гайлід Фармассет Елелсі | NUCLEOSIDE PHOSPHORAMIDATES |
| JP6069215B2 (en) | 2010-11-30 | 2017-02-01 | ギリアド ファーマセット エルエルシー | Compound |
| EP2709613B2 (en) | 2011-09-16 | 2020-08-12 | Gilead Pharmasset LLC | Methods for treating hcv |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| AU2013201532B2 (en) | 2011-10-21 | 2014-10-02 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| CH707029B1 (en) | 2011-10-21 | 2015-03-13 | Abbvie Inc | A method of treating HCV comprising at least two direct acting antiviral agents, ribavirin but not interferon. |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| US20140212491A1 (en) | 2013-01-31 | 2014-07-31 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| EP3038601B1 (en) | 2013-08-27 | 2020-04-08 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6387365B1 (en) * | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
| US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| DK1136075T3 (en) * | 1997-09-21 | 2003-04-28 | Schering Corp | Combination therapy for eradication of detectable HCV RNA in patients with chronic hepatitis C infection |
| DK0956861T3 (en) * | 1998-05-15 | 2002-07-01 | Schering Corp | Combination therapy including ribavirin and interferon-alpha for patients with chronic hepatitis C infection who have not received antiviral therapy |
-
1999
- 1999-12-16 WO PCT/US1999/027935 patent/WO2000037110A2/en not_active Application Discontinuation
- 1999-12-16 CA CA002354536A patent/CA2354536A1/en not_active Abandoned
- 1999-12-16 AU AU21570/00A patent/AU2157000A/en not_active Abandoned
- 1999-12-16 AR ARP990106462A patent/AR021876A1/en unknown
- 1999-12-16 EP EP99965894A patent/EP1140143A2/en not_active Withdrawn
- 1999-12-16 JP JP2000589220A patent/JP2003507322A/en active Pending
- 1999-12-17 PE PE1999001292A patent/PE20001369A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2157000A (en) | 2000-07-12 |
| EP1140143A2 (en) | 2001-10-10 |
| CA2354536A1 (en) | 2000-06-29 |
| WO2000037110A3 (en) | 2000-09-14 |
| WO2000037110A2 (en) | 2000-06-29 |
| PE20001369A1 (en) | 2000-12-09 |
| JP2003507322A (en) | 2003-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR021876A1 (en) | COMBINATION THERAPY FOR HCV INDUCTION OF RIBAVIRINA - INTERFERON ALFA PEGILADO | |
| CO4940414A1 (en) | THERAPY OF MODIFIED POLYETHYLENE GLYCOL INTERFERONS | |
| HUP0103423A2 (en) | Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection | |
| ES2186660T3 (en) | COMBINATION THERAPY TO ERADICATE HCV-RNA DETECTABLE IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION. | |
| AR023541A1 (en) | HCV COMBINATION THERAPY | |
| AR021226A1 (en) | COMBINATORY THERAPY WITH RIBAVIRINA-INTERFERON ALFA TO ERADICATE DETECTABLE HCV-RNA IN THOSE PATIENTS WHO PRESENT INFECTION WITH CHRONIC HEPATITIS C | |
| TW200716095A (en) | Method of treating interferon non-responders using HCV protease inhibitor | |
| BR0114636A (en) | Pegylated interferon-alpha / ribavirin hcv combination therapy | |
| BR9911076A (en) | Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis C | |
| PL1778272T3 (en) | Use of a combination of cyclosporin and pegylated interferons for treating hepatitis c (hcv) | |
| EA201000085A1 (en) | dsPHK INTRODUCED FOR THE TREATMENT OF VIRAL INFECTION | |
| AR022116A1 (en) | COMBINATION THERAPY FOR RHCAVIRINE INDUCTION HCV - INTERFERON ALFA | |
| MD2549F1 (en) | Method of treatment of the chronic viral hepatitis C | |
| CY1106388T1 (en) | THERAPY OF HEPATITIS C WITH THYMOSIN, INTEPHON, AND RIBAVIRIN | |
| JP2004529158A5 (en) | ||
| DK1311286T3 (en) | Treatment of hepatitis C with thymosin and pegylated interferon | |
| ECSP993178A (en) | COMBINATORY THERAPY WITH RIBARVIRINE-INTERFERON ALPHA TO ERADICATE HCV-DETECTABLE RNA IN THOSE PATIENTS WITH CHRONIC HEPATITIS C INFECTION | |
| TH33755A (en) | Combined therapy to eliminate detectable HCV-RNA in patients with chronic hepatitis C infection. | |
| TH53874A3 (en) | Combined HCV therapy by induction of ribavirin and pegilate-type interferon alpha. | |
| FR2791894B1 (en) | USE OF INTERFERON BETA IN THE TREATMENT OF EWING'S TUMOR |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |